A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
about
Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat modelPhase II trial of 7 days on/7 days off temozolmide for recurrent high-grade gliomaRandomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of GliomaThe combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.Evaluation of the retinoids with cisplatin and vincristine in xenograft models of neuroblastomaBevacizumab in glioblastoma multiforme.Temozolomide dosing regimens for glioma patients.Antiangiogenic therapies in glioblastoma multiforme.Targeted therapy in gliomas.Microenvironmental clues for glioma immunotherapy.Cyclooxygenase-2 in glioblastoma multiforme.Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress.Factorial clinical trials: a new approach to phase II neuro-oncology studies.2010 Society for Neuro-Oncology Annual Meeting: a report of selected studies.[Treatment of the glioma microenvironment].
P2860
Q27302402-5AD3527B-D31E-4924-BD6D-F45A51848314Q34062033-2E34DBF0-D010-4806-85EE-17D3207B08B3Q34886836-E418B44F-9F3B-439D-A521-D44F16300A59Q35895174-9F367A97-F23B-4EB6-9506-FEE50DECE0B1Q35922107-FE50D0BE-1CE9-4E69-8F72-1FE061BDAEE7Q36833480-CC9E4D52-A815-431C-865E-1C9F1E159394Q37154247-56E6A3EC-B661-455C-A4A4-9FA8B089CBA3Q37965628-1F6BE437-4523-4813-9D01-C56BA6521DB4Q37995906-23AA9647-3AE0-487C-9023-7FFEA3DB9404Q38010802-60315202-C5B5-4A48-8A45-21E3DC1E2222Q38186656-C1FBD373-5F4D-48A5-8300-FB920E43DE61Q38194054-7CE38408-9CE8-49FF-B05C-72A506AD17FAQ38969912-D1181DA6-90CC-4169-8FF6-EF968FB801B4Q39154529-CFB58386-B7A7-48B5-B2FE-737DEDE98FD2Q43098246-CB3C361E-EA45-409F-9097-FB2561AA952BQ51159183-CDDD6F04-0954-4A0F-9B94-8D36B493A9B8Q55460052-3D09F5EE-1B3E-43D8-B862-BF5026019F64
P2860
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase I factorial design stu ...... newly diagnosed glioblastoma.
@ast
A phase I factorial design stu ...... newly diagnosed glioblastoma.
@en
A phase I factorial design stu ...... newly diagnosed glioblastoma.
@nl
type
label
A phase I factorial design stu ...... newly diagnosed glioblastoma.
@ast
A phase I factorial design stu ...... newly diagnosed glioblastoma.
@en
A phase I factorial design stu ...... newly diagnosed glioblastoma.
@nl
prefLabel
A phase I factorial design stu ...... newly diagnosed glioblastoma.
@ast
A phase I factorial design stu ...... newly diagnosed glioblastoma.
@en
A phase I factorial design stu ...... newly diagnosed glioblastoma.
@nl
P2093
P2860
P356
P1433
P1476
A phase I factorial design stu ...... newly diagnosed glioblastoma.
@en
P2093
Anita Mahajan
Charles Conrad
Eric Chang
Howard Colman
Javier Gonzalez
John de Groot
Kathy Hunter
Kenneth Hess
Mark R Gilbert
Morris D Groves
P2860
P304
P356
10.1093/NEUONC/NOQ100
P577
2010-08-20T00:00:00Z